Division of General Pediatrics, Child Health Evaluation and Research (CHEAR) Unit, University of Michigan, 300 N Ingalls St, Room 6E07, Ann Arbor, MI 48109-5456, USA.
Pediatrics. 2012 Jan;129(1):e1-8. doi: 10.1542/peds.2011-0877. Epub 2011 Dec 5.
Hypertension is an increasingly common problem in adolescents yet current medical management of primary hypertension in adolescents has not been well-described.
We identified adolescents with primary hypertension by International Classification of Diseases, Ninth Revision codes and looked at prescription patterns chronologically for antihypertensive drug class prescribed and the specialty of prescribing physician. We also examined patient demographics and presence of obesity-related comorbidities.
During 2003-2008, there were 4296 adolescents with primary hypertension (HTN); 66% were boys; 73% were aged 11 to 14 years; 53% were black, 41% white, and 4% Hispanic; and 48% had obesity-related comorbidity. Twenty-three percent (977) received antihypertensive prescription. White subjects (odds ratio [OR]: 1.61; confidence interval [CI]: 1.39-1.88), older adolescents (≥15 years, OR: 2.11; CI: 1.79-2.48), and those with comorbidity (OR: 1.57; CI: 1.36-1.82) were more likely to receive antihypertensive prescriptions controlling for gender and years of Medicaid eligibility in logistic regression. Angiotensin converting enzyme inhibitors were the most frequently prescribed monotherapy. Nearly two-thirds of adolescents received prescriptions from adult primary care physicians (PCPs) only. More than one-quarter of adolescents who received a prescription received combination therapy, which was most often prescribed by adult PCPs.
Adult PCPs were the leading prescribers of antihypertensives for adolescents with primary HTN. Race differences exist in physicians' prescribing of antihypertensives to adolescents with primary HTN. The choice of antihypertensives by physicians of different specialties warrants additional study to understand the underlying rationale for treatment decisions and to determine treatment effectiveness.
高血压在青少年中越来越常见,但目前对青少年原发性高血压的医学管理尚未得到充分描述。
我们通过国际疾病分类第九版代码确定了原发性高血压的青少年,并按时间顺序查看了所开降压药类别的处方模式和开具处方医生的专业。我们还检查了患者的人口统计学特征和肥胖相关合并症的存在情况。
在 2003 年至 2008 年间,共有 4296 名青少年患有原发性高血压(HTN);66%为男性;73%年龄在 11 至 14 岁之间;53%为黑人,41%为白人,4%为西班牙裔;48%有肥胖相关合并症。23%(977 人)接受了降压药物治疗。白人患者(比值比[OR]:1.61;置信区间[CI]:1.39-1.88)、年龄较大的青少年(≥15 岁,OR:2.11;CI:1.79-2.48)和有合并症的青少年(OR:1.57;CI:1.36-1.82),在逻辑回归中按性别和医疗补助资格年限校正后,更有可能接受降压药物治疗。血管紧张素转换酶抑制剂是最常开的单一疗法。近三分之二的青少年仅接受成人初级保健医生(PCP)的处方。接受处方的青少年中,超过四分之一接受了联合治疗,这种治疗最常由成人 PCP 开出。
成人 PCP 是为原发性高血压青少年开降压药的主要医生。不同种族的医生在为原发性高血压青少年开降压药方面存在差异。不同专业医生选择的降压药值得进一步研究,以了解治疗决策的潜在依据,并确定治疗效果。